RSD 1122

Drug Profile

RSD 1122

Alternative Names: RSD1122

Latest Information Update: 25 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiome Pharma
  • Class
  • Mechanism of Action Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atrial fibrillation

Most Recent Events

  • 25 Feb 2003 Discontinued - Preclinical for Atrial fibrillation in Canada (PO)
  • 25 Feb 2003 Discontinued - Preclinical for Atrial fibrillation in Europe (PO)
  • 04 Apr 2002 AstraZeneca have terminated its license for the clinical development of RSD 1122
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top